Bolt Biotherapeutics, Inc. (BOLT)
Company Description
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer.
The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.
It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer.
The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F.
Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015.
Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
Country | United States |
Founded | 2015 |
IPO Date | Feb 5, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 100 |
CEO | Dr. Randall C. Schatzman Ph.D. |
Contact Details
Address: 900 Chesapeake Drive Redwood City, California 94063 United States | |
Phone | 650-665-9295 |
Website | boltbio.com |
Stock Details
Ticker Symbol | BOLT |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $20.00 |
CIK Code | 0001641281 |
CUSIP Number | 097702104 |
ISIN Number | US0977021049 |
Employer ID | 47-2804636 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Randall C. Schatzman Ph.D. | Chief Executive Officer and Director |
Dr. Edgar George Engleman M.D. | Founder and Independent Director |
William P. Quinn | Chief Financial Officer and Secretary |
Grant Yonehiro C.F.A., M.B.A. | Chief Business Officer |
Dr. Edith A. Perez M.D. | Chief Medical Officer |
Wesley Burwell | Vice President and Head of Human Resources |
Dr. Nathan Ihle Ph.D. | Senior Vice President of Pharmaceutical Operations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 21, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
Mar 21, 2024 | 10-K | Annual Report |
Mar 21, 2024 | 8-K | Current Report |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 12, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
Nov 9, 2023 | 10-Q | Quarterly Report |
Nov 9, 2023 | 8-K | Current Report |
Aug 7, 2023 | 10-Q | Quarterly Report |